Please login to the form below

Not currently logged in
Email:
Password:

Viaskin Peanut

This page shows the latest Viaskin Peanut news and features for those working in and with pharma, biotech and healthcare.

EU authorises Aimmune’s peanut allergy treatment Palforzia

EU authorises Aimmune’s peanut allergy treatment Palforzia

Aimmune’s potential rival, DBV Technologies, has not had as much success with getting its peanut allergy treatment approved. ... In August, DBV announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (FDA

Latest news

  • FDA knocks back DBV’s peanut allergy therapy once again FDA knocks back DBV’s peanut allergy therapy once again

    drug. Like Palforzia, the rationale for Viaskin Peanut is to expose people with peanut allergy to small amounts of antigen over time to encourage the immune system to develop tolerance. ... Analysts at Baird have suggested that with a weaker clinical

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy,” added Marks. ... California biotech Aimmune has been in a race to

  • Aimmune gets FDA panel backing for peanut allergy therapy Aimmune gets FDA panel backing for peanut allergy therapy

    Peanut allergies are the leading cause of death from food-induced allergic reactions in the US. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns about

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... This is an important milestone for DBV, as we are one step closer towards

  • Aimmune wins over ICER for peanut allergy product Aimmune wins over ICER for peanut allergy product

    for the 1.6m people with peanut allergy in the US, and presented its case at an ICER meeting yesterday. ... Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Springer Nature

Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...